Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly/BI's Basaglar: A Rosier Outlook For US Biosimilars?

31 Jan 2018

• By Jessica Merrill

Diabetes

Related Content

And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer

29 Sep 2017

Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

29 Nov 2017

Merck's Lantus Copy Lusduna Poised For US Market Pending Litigation

20 Jul 2017

Sanofi's Admelog, a Humalog Follow-On, Approved In US As 'Black Hole' For Insulins Looms

11 Dec 2017

Just Do It: Lilly CEO Ricks On Rebates At The Pharmacy Counter

31 Jan 2018

Rebate Pass-Through Would Lower, Not Raise, Medicare Spending – PhRMA

19 Jan 2018

UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

22 Sep 2016

Sanofi Settlement With Lilly Paves The Way For Biosimilar Lantus

28 Sep 2015

FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear

23 May 2016

Related Companies

Eli Lilly and Company

Boehringer Ingelheim GmbH

Sanofi

Pfizer Inc.

Johnson & Johnson

Celltrion, Inc.

Merck & Co., Inc.

Samsung Bioepis Co., Ltd.

Viatris Inc.

Novartis AG

Pfizer Inc.

Additional Topics

Biosimilars Sales & Earnings Commercial Metabolic Disorders BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.